• OPEN AN ACCOUNT
Indian Indices
Sensex
73,852.90 -876.37
( -1.17%)
Global Indices
Nasdaq
51,986.54 -36.87
(-0.07%)
Dow Jones
7,712.39 31.95
(0.42%)
Hang Seng
63,869.15 -1,047.55
(-1.61%)
Nikkei 225
10,765.28 -116.62
(-1.07%)
Forex
USD-INR
94.77 -0.08
(-0.08%)
EUR-INR
106.47 0.12
(0.11%)
GBP-INR
126.26 0.54
(0.43%)
JPY-INR
0.60 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Kataria Industries Ltd
Industry :  Steel - Medium / Small
BSE Code
ISIN Demat
Book Value()
92930
INE0SVY01018
56.3053813
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KATARIA
27.43
316.51
EPS(TTM)
Face Value()
Div & Yield %
5.36
10
0
 

bfl asset finvest ltd
Eris Lifesciences gains after Q1 PAT climbs 21% YoY to rs 142 cr
Jul 29,2026
Revenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter.

Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27.

EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26.

During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter.

Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.